Office of Technology Development - Sponsored Research Agreements Join us as we congratulate the Principal Investigators of new industry sponsored research agreements listed below. (Based on information available as of 2/3/11):

January 2011

Principal Investigator: Matthew G. Fury, MD, PhD Department/Program: Medicine/Head and Neck Oncology Service Project Title: Phase I Study of BKM120 + Carboplatin + for Patients with Advanced Solid Tumors. Total Award Amount: $271,177 Award Date: 01/04/11 Awarding Agency: Novartis Pharmaceuticals Corporation Principal Investigator: Lee M. Krug, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: Phase II Study of ADI-PEG 20 in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer Total Award Amount: $150,544 Award Date: 01/08/11 Awarding Agency: Ludwig Institute for Cancer Research

Principal Investigator: Craig Moskowitz, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase 2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults with Relapsed or Refractory Hodgkin Lymphoma Total Award Amount: $96,467 Award Date: 01/20/11 Awarding Agency: Plexxikon Inc.

Principal Investigator: Eileen O'Reilly, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Phase II, Open-Label, Multicenter Study to Evaluate the Antitumor Efficacy of CO-101 for Infustion as a Second-Line Therapy for Gemcitabine Refractory Patients with Stage IV Pancreatic Adenocarcinoma and No Tumor hENT1 Expression Total Award Amount: $171,261 Award Date: 01/12/11 Awarding Agency: Clovis Oncology

Principal Investigator: Antonio M. Omuro, MD Department/Program: Neurology/Neurology Service Project Title: An Exploratory Pharmacodynamic Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma Who Are Candidates for Surgical Resection Total Award Amount: $168,422 Award Date: 01/20/11 Awarding Agency: Exelixis, Inc. Principal Investigator: Dana Rathkopf, MD, PhD Department/Program: Medicine / Genitourinary Oncology Service Project Title: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors Total Award Amount: $392,849 Award Date: 01/07/11 Awarding Agency: Exelixis, Inc.

Principal Investigator: Dana Rathkopf, MD, PhD Department/Program: Medicine / Genitourinary Oncology Service Project Title: A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors Total Award Amount: $34,124 Award Date: 01/12/11 Awarding Agency: Exelixis, Inc.

Principal Investigator: Naiyer A. Rizvi, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety and Antitumor Activity of MEDI-3617, a Fully Human Monoclonal Antibody Directed Against ANG2, in Adult Subjects with Advanced Solid Tumors. Total Award Amount: $225,193 Award Date: 01/11/11 Awarding Agency: MedImmune

Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/ and Sarcoma Service Project Title: A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ALN-VSP02 in Patients with Advanced Solid Tumors with Liver Involvement. Total Award Amount: 260,061 Award Date: 01/18/11 Awarding Agency: , Inc.

Principal Investigator: Andrew D. Seidman, MD Department/Program: Medicine/Breast Cancer Medicine Service Project Title: A Phase II Study of as First-Line Therapy for Subjects with Metastatic Breast Cancer Total Award Amount: $232,781 Award Date: 01/25/11 Awarding Agency: Genta Incorporated

February 2011

Principal Investigator: Hani Hassoun, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase II, Multi-Center, Non-Randomized, Open-Label Study of TK1258 in Patients with Relapsed or Refractory Multiple Myeloma, Who Are With or Without t(4; 14) Translocation Total Award Amount: $129,585 Award Date: 02/10/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Nicole Lamanna, MD Department/Program: Medicine/Leukemia Service Project Title: A Phase 2 Single Arm Study to Investigate the Safety and Clinical Activity of CAL-101 in Combination with Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Total Award Amount: $230,639 Award Date: 02/18/11 Awarding Agency: Veeda Oncology/ Calistoga Pharmaceuticals, Inc.

Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer who Have Progressed After -Based Total Award Amount: $171,279 Award Date: 02/17/11 Awarding Agency: Cougar Biotechnology, Inc

Principal Investigator: Elizabeth A. Morris, MD, FACR Department/Program: Radiology/Breast Imaging Service Project Title: An Open Label, Multi-center, Phase 3 Study with Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist) in Patients with Newly diagnosed Breast Cancer Referred for Contrast-Enhanced Breast MRI Total Award Amount: $147,231.90 Award Date: 02/01/11 Awarding Agency: Bayer Corporation

Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC Coordinating Center. Phase 2 Study of a Single Agent Tesetaxel in Chemotherapy-Naive and Chemotherapy Exposed Patients who have Progressive, Castration-Resistant Prostrate Cancer. Total Award Amount: $114,436.30 Award Date: 02/09/11 Awarding Agency: Genta Incorporated

Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $35,167 Award Date: 02/01/11 Awarding Agency: Enzon, Inc.

Principal Investigator: Tanya M. Trippett, MD Department/Program: Pediatrics Project Title: IIS: A Phase I/II Clinical Study of Vorinostat in Combination with Etoposide in Pediatric Patient Total Award Amount: $30,428 Award Date: 02/09/11 Awarding Agency: Merck & Co

March 2011

Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase II Open-Label, Two-Cohort, Multicenter Study of GSK2118436 as a Single Agent in Treatment Naive and Previously Treated Subjects with BRAF Mutation- Positive Metastatic Melanoma to the Brain Total Award Amount: $217,110 Award Date: 03/02/11 Awarding Agency: GlaxoSmithKline

Principal Investigator: Daniel C. Danila, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: A Phase 1 aJ1 b, Open-Label Study Evaluating the Safety and Tolerability of EZN-4176, an Androgen Receptor mRNA Antagonist, in Adult Patients with Castration- Resistant Prostate Cancer Total Award Amount: $692,267 Award Date: 03/01/11 Awarding Agency: Enzon, Inc.

Principal Investigator: Steven M. Horwitz, MD Department/Program: Medicine/Lymphoma Service Project Title: Physician Registry Study Total Award Amount: $233,759 Award Date: 03/29/11 Awarding Agency: Allos Therapeutics, Inc.

Principal Investigator: Nancy E. Kemeny, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Randomized Phase II Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients with Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer Total Award Amount: $406,900 Award Date: 03/07/11 Awarding Agency: Inc. Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $136,037 Award Date: 03/03/11 Awarding Agency:

Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: Lab Service Agreement Related to CT EZN 4176 Total Award Amount: $682,851 Award Date: 03/18/11 Awarding Agency: Enzon, Inc.

Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC CC Service Agreement Total Award Amount: $76,463 Award Date: 03/19/11 Awarding Agency: Millennium Pharmaceuticals, Inc.

Principal Investigator: Leonard H. Wexler, MD Department/Program: Pediatrics Project Title: A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer Total Award Amount: $50,000 Award Date: 03/30/11 Awarding Agency: Bristol-Myers Squibb/National Cancer Institute

April 2011

Principal Investigator: Ellin Berman, MD Department/Program: Medicine/Leukemia Service Project Title: A Pivotal Phase 2 Trial of AP24534 in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Total Award Amount: $299,983 Award Date: 04/05/11 Awarding Agency: ARIAD Pharmaceuticals, Inc./Industrial Agreements

Principal Investigator: Jorge A. Carrasquillo, MD Department/Program: Radiology/Nuclear Medicine Service Project Title: ImmunoPET Research Collaboration Agreement Total Award Amount: $26,076 Award Date: 04/28/11 Awarding Agency: , Inc.

Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase III Randomized, Open-Label Study Comparing GSK2118436 to DTIC in Previously Untreated Subjects with BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma Total Award Amount: $310,798 Award Date: 04/06/11 Awarding Agency: GlaxoSmithKline

Principal Investigator: Daniel C. Danila, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: SOW #DST4964g Total Award Amount: $2,583,478 Award Date: 04/21/11 Awarding Agency: Genentech, Inc.

Principal Investigator: Hakim Djaballah, PhD Department/Program: High-Throughput Drug Screening Facility Project Title: Work Statement for HTS Screening - Under the Master Service Agreement SK2010-0914 Total Award Amount: $14,606.74 Award Date: 04/22/11 Awarding Agency: Cold Spring Harbor Laboratory

Principal Investigator: Mark L. Heaney, MD, PhD Department/Program: Medicine/Hematology Service/Leukemia Service Project Title: A Phase-3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare Efficacy and Safety of Pomalidomide Versus Placebo in Subjects with MPN-Associated Myelofibrosis and Red Blood Cell-Transfusion-Dependence Total Award Amount: $224,800.93 Award Date: 04/05/11 Awarding Agency: Celgene Corporation

Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: SRA Novartis Levine Jak2+HSP90 Inhibitor in a PMF disease model Total Award Amount: $147,337 Award Date: 04/16/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Vincent A. Miller, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine- Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients with Stage IV Nonsquamous Non-Small Lung Cancer (NSCLC) Total Award Amount: $228,429 Award Date: 04/26/11 Awarding Agency: ImClone Systems, Inc. Principal Investigator: David B. Solit, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: Biomarkers of PLX4032 Response in BRAFV600E Mutant Colon Cancers Total Award Amount: $5,240 Award Date: 04/11/11 Awarding Agency: Hoffmann-La Roche Inc.

May 2011

Principal Investigator: Michael F. Berger, PhD Department/Program: Pathology/Genetics Research Project Title: SOW Under Master Res Agrt SK2011-0530 - A Study to Investigate the Concordance of the Foundation Medicine Comprehensive Genomic Profiling Assay with Mass Spectrometry and Sanger Sequencing Assays for Detecting Targeted Mutations in Archived FFPE Specimens Total Award Amount: $22,500 Award Date: 05/25/11 Awarding Agency: Foundation Medicine, Inc.

Principal Investigator: Bernard H. Bochner, MD Department/Program: Surgery/Urology Service Project Title: CTA Tengion Bochner TNG-CL009 Total Award Amount: $335,178 Award Date: 05/05/11 Awarding Agency: Tengion Inc.

Principal Investigator: Michelle S. Bradbury, MD, PhD Department/Program: Radiology/Neuroradiology Service Project Title: Translational Research Funding Agreement for Grant with Participating Interest Total Award Amount: $208,333.33 Award Date: 05/25/11 Awarding Agency: Partnership Foundation

Principal Investigator: Ian Ganly, MD, PhD Department/Program: Surgery/Head and Neck Service Project Title: CO2 Laser Versus Monopolar Cautery Total Award Amount: $45,753 Award Date: 05/10/11 Awarding Agency: OmniGuide, Inc.

Principal Investigator: Steven M. Larson, MD Department/Program: Radiology/Nuclear Medicine/Molecular Pharmacology & Chemistry Project Title: SRA: Software Evaluation of Advantage Workstation (Evaluation 2 PETVcar2) Total Award Amount: $4,227.73 Award Date: 05/16/11 Awarding Agency: GE Healthcare Principal Investigator: Nikoletta Lendvai, MD, PhD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Pilot Study of recMAGE-A3 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Total Award Amount: $84,068 Award Date: 05/26/11 Awarding Agency: Ludwig Institute for Cancer Research/GlaxoSmithKline

Principal Investigator: Nikoletta Lendvai, MD, PhD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma Total Award Amount: $370,765 Award Date: 05/05/11 Awarding Agency: Onyx Pharmaceuticals

Principal Investigator: Robert J. Motzer, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study of BMS-936558 (MDX- 1106) in Subjects with Progressive Advanced/Metasdtatic Clar-Cell Renal Cell Carcinoma Who Have Received Prir Anti-Angiogenic Therapy Total Award Amount: $230,018 Award Date: 05/13/11 Awarding Agency: Bristol-Myers Squibb

Principal Investigator: Neal Rosen, MD, PhD Department/Program: Medicine/Breast Cancer Medicine/Molecular Pharmacology & Chemistry Project Title: SRA Preclinical Evaluation of Combination Treatment MEK and AKT inhibitors Total Award Amount: $159,033 Award Date: 05/24/11 Awarding Agency: Merck & Co/AstraZeneca

Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC Genta Service Agreement Total Award Amount: $113,722 Award Date: 05/04/11 Awarding Agency: Genta Incorporated

Principal Investigator: Neil H. Segal, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: Phase I Parallel Protocol of MK 8669 (Ridaforolimus) + MK 2206 and MK 8669 (Radaforolimus) + MK 0752 Doublets (MKMK) in Patients with Advanced Cancer Total Award Amount: $355,311 Award Date: 05/13/11 Awarding Agency: Radiological Society of North America June 2011

Principal Investigator: Ghassan K. Abou-Alfa, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Randomized Double-Blind, Multi-Center Phse 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy Total Award Amount: $535,200 Award Date: 06/21/11 Awarding Agency: PPD Development, Inc.

Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: SOW #ML22597 RO5185426 Total Award Amount: $236,721 Award Date: 06/29/11 Awarding Agency: Genentech, Inc.

Principal Investigator: John F. Gerecitano, MD, PhD Department/Program: Medicine/Lymphoma Service Project Title: A Multicenter, Open-Label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relpased or Refractory De Novo Diffuse Large B-Cell Lymphoma Total Award Amount: $200,940 Award Date: 06/13/11 Awarding Agency: Pharmacyclis, Inc.

Principal Investigator: José G. Guillem, MD, FACS, FASCRS Department/Program: Surgery/Colorectal Service Project Title: Phase III Placebo-Controlled Trial of Celecoxib in Genotype Positive Subjects with Familial Adenomatous Polyposis Total Award Amount: $263,130 Award Date: 06/08/11 Awarding Agency: , Inc.

Principal Investigator: Hani Hassoun, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Pilot Study of Bortezomib/Dexamethasone (BD), Followed by Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone for the Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated with Multiple Myeloma and AL Amyloidosis Total Award Amount: $118,225 Award Date: 06/23/11 Awarding Agency: Millennium Pharmaceuticals, Inc.

Principal Investigator: Mary Louise Keohan, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: BAY73-4506/14874 Phase 3 Regerafenib 11-036 Total Award Amount: $218,927 Award Date: 06/14/11 Awarding Agency: Pharmaceutical Research Associates, Inc.

Principal Investigator: Paul A. Marks, PhD Department/Program: Medicine/Departmental/Cell Biology Project Title: HDAC-6 Collaboration with Columbia University Total Award Amount: $340,011 Award Date: 06/01/11 Awarding Agency: Servier, Les Laboratoires

Principal Investigator: Matthew J. Matasar, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Ofatumumab versus Rituximab Salvage Chemoimmunotherapy Followed y ASCT in Relapsed or Refractory DLBCL, OMB110928 Total Award Amount: $466,104 Award Date: 06/17/11 Awarding Agency: GlaxoSmithKline

Principal Investigator: Ana Maria Molina, MD Department/Program: Medicine Project Title: A Phase II Study of Investigating the Efficacy of Combining RAD001 (Everolimus) and Bevacizumab in Advanced Renal Cell Cancer with Non-Clear Cell Histology. Total Award Amount: $289,550 Award Date: 06/01/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Neal Rosen, MD, PhD Department/Program: Medicine/Breast Cancer Medicine/Molecular Pharmacology & Chemistry Project Title: SRA Bayer Rosen PI3K Signaling Output Total Award Amount: $62,007 Award Date: 06/22/11 Awarding Agency: Bayer Corporation

Principal Investigator: Neil H. Segal, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Phase l Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients with Colorectal Cancer Total Award Amount: $18,632 Award Date: 06/23/11 Awarding Agency: Immunomedics, Inc.

Principal Investigator: Larry J. Smith, PhD Department/Program: Laboratory Medicine Project Title: Evaluation One Sample Procurement Protocol and One Evaluation Protocol with IL Products Total Award Amount: $7,250 Award Date: 06/27/11 Awarding Agency: Instrumentation Laboratory Company

July 2011

Principal Investigator: Ghassan K. Abou-Alfa, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Randomized Double-Blind, Multi-Center Phse 3 Study of ADI-PEG 20 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Failed Prior Systemic Therapy Total Award Amount: $535,200 Award Date: 07/11/11 Awarding Agency: PPD Development, Inc.

Principal Investigator: Richard D. Carvajal, MD Department/Program: Medicine/Melanoma & Sarcoma Service Project Title: Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects with Metastatic Melanoma Total Award Amount: $278,312 Award Date: 07/27/11 Awarding Agency: Morphotek, Inc.

Principal Investigator: Steven M. Horwitz, MD Department/Program: Medicine/Lymphoma Service Project Title: A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) as Front-Line Therapy in Patients with Systemic Anaplastic Large Cell Lymphoma Total Award Amount: $374,725 Award Date: 07/27/11 Awarding Agency: Seattle Genetics, Inc.

Principal Investigator: Steven M. Horwitz, MD Department/Program: Medicine/Lymphoma Service Project Title: Research and Data Use Agreement Total Award Amount: $11,111 Award Date: 07/18/11 Awarding Agency: Celgene Corporation

Principal Investigator: Steven M. Horwitz, MD Department/Program: Medicine/Lymphoma Service Project Title: Historical Database for Patients with Newly Diagnosed Peripheral T-Cell Lymphoma (PTCL) Total Award Amount: $11,481 Award Date: 07/13/11 Awarding Agency: Allos Therapeutics, Inc.

Principal Investigator: Yelena Y. Janjigian, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: SRA BIPI Janjigian Her2 PET Total Award Amount: $49,400 Award Date: 07/18/11 Awarding Agency: Boehringer Ingelheim Corporation

Principal Investigator: Jason S. Lewis, PhD Department/Program: Radiology/Radiochemistry Service Project Title: SRA GE URI Lewis pH Peptide (GE-215) Optimization Total Award Amount: $192,000 Award Date: 07/21/11 Awarding Agency: GE Healthcare

Principal Investigator: Vincent A. Miller, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase I/II Trial of HSP90 Inhibitor AUY-922 in Patients with Lung Adenocarcinoma with Acquired Resistance to EGFR Tyrosine Kinase Inhibitors Total Award Amount: $234,466.66 Award Date: 07/06/11 Awarding Agency: Northwestern University/Novartis Pharmaceuticals Corporation

Principal Investigator: Naiyer A. Rizvi, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: Phase 1 AC480 Total Award Amount: $398,762 Award Date: 07/25/11 Awarding Agency: Ambit Biosciences Corp.

August 2011

Principal Investigator: Paul Glare, MD Department/Program: Pain and Palliative Care Service Project Title: Phase 2 Tanezumab Total Award Amount: $119,347 Award Date: 08/30/11 Awarding Agency: Pfizer, Inc./INC Research, Inc.

Principal Investigator: Paul A. Hamlin, MD Department/Program: Medicine/Lymphoma Service Project Title: Ofatumumab Alone or in Conjuction with Bendamustine for Non-Transplant Eligible Unreated Mantle Cell Lymphoma Total Award Amount: $690,096.30 Award Date: 08/02/11 Awarding Agency: GlaxoSmithKline

Principal Investigator: Adriana Haimovitz-Friedman, PhD Department/Program: Molecular Pharmacology & Chemistry Project Title: SRA 7 Oaks Haimovitz-Friedman Total Award Amount: $129,134.16 Award Date: 08/11/11 Awarding Agency: 7 Oaks Pharmaceuticals

Principal Investigator: Mark Kris, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: Coordinating Investigator Agreement Total Award Amount: $5,000 Award Date: 08/03/11 Awarding Agency: Boehringer Ingelheim Pharmaceuticals, Inc.

Principal Investigator: Howard Scher, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: PCCTC Genentech Coordinating Center Total Award Amount: $57,981 Award Date: 08/11/11 Awarding Agency: Genentech, Inc.

Principal Investigator: Tanya M. Trippett, MD Department/Program: Pediatrics Project Title: Clinical Trial POETIC - Dr. Trippett Plerixafor study Total Award Amount: $24,630 Award Date: 08/08/11 Awarding Agency: Children's Healthcare of Atlanta, Inc.

Principal Investigator: Tanya M. Trippett, MD Department/Program: Pediatrics Project Title: Data Service Agr-Plerixafor-Trippett Total Award Amount: $39,845 Award Date: 08/11/11 Awarding Agency: Children's Healthcare of Atlanta, Inc.

September 2011

Principal Investigator: Elisa DeStanchina, PhD Department/Program: Molecular Pharmacology & Chemistry Project Title: Lab Services Celegene DeStanchina NK Cell Therapy Total Award Amount: $99,000 Award Date: 09/08/11 Awarding Agency: Celgene Corporation

Principal Investigator: Todd Rosenblat, MD Department/Program: Medicine/Leukemia Service Project Title: A Phase 3, Randomized, Controlled double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (VALOR) Total Award Amount: $136,604 Award Date: 09/22/11 Awarding Agency: Sunesis Pharmaceuticals, Inc. Principal Investigator: Eric J. Sherman, MD Department/Program: Medicine/Head and Neck Oncology Service Project Title: An Open-Label, Ulti-Center Phase II Study of the BRAF Inhibitor RO5185426 in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine Total Award Amount: $344,053 Award Date: 09/22/11 Awarding Agency: Genentech, Inc.

Principal Investigator: Nian Wu, PhD Department/Program: Shared Core Facilities Project Title: Services Biozone Pharmaceuticals Total Award Amount: $38,331.45 Award Date: 09/28/11 Awarding Agency: Biozone Pharmaceuticals Inc

October 2011

Principal Investigator: Christopher G. Azzoli, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Multi-Center, Open-Label, Extension Study to Allow Continued Treatment of Patients Who Have Participated in Allos-Sponsored Pralatrexate Studies Total Award Amount: $44,352 Award Date: 10/18/11 Awarding Agency: Allos Therapeutics, Inc.

Principal Investigator: Christopher G. Azzoli, MD Department/Program: Medicine/Thoracic Oncology Service Project Title: Phase 2 Trial of Neoadjuvant Pemetrexed Plus Cisplatin for Patients with Resectable Non-Squamous Non-Small Cell Lung Cancer with Switch to Alternative Chemotherapy in On-Responders (NAPSTER) Total Award Amount: $370,370.37 Award Date: 10/04/11 Awarding Agency:

Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Single Center Phase II Trial of Vemurafenib (RO5185426) in Poor Performance Status Patients with Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E BRAF Mutation Total Award Amount: $138,497 Award Date: 10/13/11 Awarding Agency: Genentech, Inc.

Principal Investigator: Hani Hassoun, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase II Clinical Trial of Lenalidomide Intensification in Patients with Serologic/Asymptomatic Progression of Multiple Myeloma while on Lenalidomide Maintenance After Autologous Stem Cell Transplantation Total Award Amount: $148,148 Award Date: 10/25/11 Awarding Agency: Celgene Corporation

Principal Investigator: Jason Konner, MD Department/Program: Medicine / Gynecologic Medical Oncology Service Project Title: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS-22M6E Given as Monotherapy in Subjects with Malignant Solid Tumors that Express Nectin-4 Total Award Amount: $807,439 Award Date: 10/11/11 Awarding Agency: Agensys Inc.

Principal Investigator: Yueming Li, PhD Department/Program: Molecular Pharmacology & Chemistry Project Title: Research Agreement for Testing Pfizer's Compounds Using Dr. Li's Gamma- Secretase Assay Total Award Amount: $70,720 Award Date: 10/13/11 Awarding Agency: Pfizer, Inc.

Principal Investigator: Ana Maria Molina, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: A Phase 1b/2 Study of BEZ235 in Patients with Advanced Renal Cell Carcinoma (RCC) Total Award Amount: $515,769 Award Date: 10/10/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Genovefa Papanicolaou, MD Department/Program: Medicine/Infectious Diseases Service Project Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs) Total Award Amount: $321,668 Award Date: 10/19/11 Awarding Agency: Merck & Co

Principal Investigator: Jedd D. Wolchok, MD, PhD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase I/II Trial of Vemurafenib (RG7204) and Ipilimumab in Subjects with V600 BRAF Mutation-Positive Metastatic Melanoma Total Award Amount: 153,780 Award Date: 10/31/11 Awarding Agency: Exelixis, Inc.

November 2011 Principal Investigator: Paul B. Chapman, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: Pfizer CTI for Paul Chapman R24 Total Award Amount: $127,855 Award Date: 11/25/11 Awarding Agency: Pfizer, Inc.

Principal Investigator: Alan L. Ho, MD, PhD Department/Program: Medicine/Head and Neck Oncology Service Project Title: A Phase I, Open-Label, Multiple-Escalating-Dose Study of DS-7423, an Orally Administered Dual P12K/mTOR Inhibitor, in Subjects with Advanced Solid Tumors Total Award Amount: $417,461.48 Award Date: 11/21/11 Awarding Agency: Daiichi Pharmaceutical

Principal Investigator: Craig Moskowitz, MD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients with Relapsed or Refractory Hodgkin Lymphoma Total Award Amount: $58,080 Award Date: 11/29/11 Awarding Agency:

Principal Investigator: Robert J. Motzer, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: A Phase II, Open Label, Randomized Study of GDC-0980 Versus Everolimus in Patients wtih Metastatic Renal Cell Carcinoma who have Progressed on or Following VEGF- Targeted Therapy Total Award Amount: $190,259.26 Award Date: 11/29/11 Awarding Agency: Genentech, Inc.

Principal Investigator: Gregory J. Riely, MD, PhD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase I, Multicenter, Open-Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients with Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK) Total Award Amount: $403,221.26 Award Date: 11/18/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Gregory J. Riely, MD, PhD Department/Program: Medicine/Thoracic Oncology Service Project Title: A Phase 1b/2 Study of IPI-504 in Combination with Everolimus in Patients with KRAS Mutant NSCLC Total Award Amount: $191,614 Award Date: 11/10/11 Awarding Agency: Infinity Pharmaceuticals, Inc.

Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: A Phase Ib, Open-Label, Multi-Center, Dose Escalation and Expansion Study of an Orally Administered Combination of BKM120 Plus MEK162 in Adult Patients with Selected Advanced Tumors Total Award Amount: $443,121.48 Award Date: 11/15/11 Awarding Agency: Novartis Pharmaceuticals Corporation

Principal Investigator: Neil H. Segal, MD Department/Program: Medicine/Gastrointestinal Oncology Service Project Title: A Phase 1 Study of PF-05082566 as a Single Agent in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin's Lymphoma (NHL) Total Award Amount: $486,108 Award Date: 11/11/11 Awarding Agency: Pfizer, Inc.

Principal Investigator: Jedd D. Wolchok, MD, PhD Department/Program: Medicine/Melanoma and Sarcoma Service Project Title: Phase II Study to Evaluate the Safety, Tolerability and Efficacy of CT-011 Administered Intravenously to Patients with Metastatic Melanoma Total Award Amount: $584,453 Award Date: 11/10/11 Awarding Agency: CureTech Ltd.

Principal Investigator: Michael J. Zelefsky, MD Department/Program: Radiation Oncology/Brachytherapy Service/External Beam Radiotherapy Service, Manhattan Project Title: A Randomized Controlled Trial of ProstAtak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer Total Award Amount: $48,148 Award Date: 11/04/11 Awarding Agency: Advantagene, Inc.

December 2011

Principal Investigator: Dean F. Bajorin, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: CTA Dendreon Total Award Amount: $197,020 Award Date: 12/05/11 Awarding Agency: Dendreon Corporation Principal Investigator: Andrea Cercek Hanjis, MD Department/Program: Gastrointestinal Oncology Project Title: Open-Label, Phase 1 Study of LOR-253 HCI in Patients with Advanced or Metastatic Tumours Total Award Amount: $371,452 Award Date: 12/06/11 Awarding Agency: Lorus Therapeutics Inc

Principal Investigator: Richard N. Kolesnick, MD Department/Program: Medicine/Endocrinology/Molecular Pharmacology & Chemistry Project Title: Selection of an Anti-ceramide Mitigator of Acute Radiation Toxicity of the GI Tract for Clinical Development Total Award Amount: $98,081 Award Date: 12/12/11 Awarding Agency: Ceramide Therapeutics, LLC/National Institute of Allergy and Infectious Diseases

Principal Investigator: Nikoletta Lendvai, MD, PhD Department/Program: Medicine/Hematology Service/Lymphoma Service Project Title: Multiple Myeloma Expanded Access Protocol for Patients with Relapsed Refractory Disease Total Award Amount: $326,327 Award Date: 12/16/11 Awarding Agency: Onyx Pharmaceuticals

Principal Investigator: Andrew Lassman, MD Department/Program: Neurology/Neurology Service Project Title: Research Ties with Phase I/II Trial of Temsirolimus and Perifosine for Recurrent or Progressive Malignant Gliomas (NCI #8249) Total Award Amount: $52,000 Award Date: 12/20/11 Awarding Agency: Keryx , Inc.

Principal Investigator: Vicky Makker, MD Department/Program: Gynecologic Medical Oncology Project Title: A Phase 2 Evaluation of Trc105 in the Treatment of Recurrent Ovarian, fallopian Tube, or Primary Peritoneal Carcinoma Total Award Amount: $193,560 Award Date: 12/10/11 Awarding Agency: TRACON Pharmaceuticals, Inc.

Principal Investigator: Michael Morris, MD Department/Program: Medicine/Genitourinary Oncology Service Project Title: A Phase 3, Ramdomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednison in Patients with Chermotherapy- Naive Metastatic Castration-Resistant Prostate Cancer Total Award Amount: $625,870 Award Date: 12/20/11 Awarding Agency: Millennium Pharmaceuticals, Inc.

Principal Investigator: Julie Teruya-Feldstein, MD Department/Program: Surgical Pathology Diagnostic Services/Hematopathology Project Title: SRA Evaluation of the Potential Utility of ADCs Total Award Amount: $71,957 Award Date: 12/27/11 Awarding Agency: Seattle Genetics, Inc.